Life sciences clause bank

Discover essential clauses for life sciences contracts that cater to the distinct needs of the industry. Our comprehensive clause bank offers expertly drafted provisions, ensuring your agreements are robust and compliant. Whether handling clinical trials, intellectual property, or regulatory matters, utilise precise contract language to safeguard your interests and streamline negotiations.

View Life Sciences by content type:

News
Practice notes
Precedents
Q&As

Sub Topics We Cover

Boilerplate clauses Definitions Execution Life sciences clauses

Latest Life Sciences News

MHRA secures £3.6 million in funding to expand AI Airlock programme

MHRA secures £3.6 million in funding to expand AI Airlock programme

The Medicines and Healthcare products Regulatory Agency (MHRA) has secured £3.6 million in funding over three years to expand its Artificial...

Team-NB submits feedback on proposed revision of EU medical device rules

Team-NB submits feedback on proposed revision of EU medical device rules

The European Association of Medical Devices Notified Bodies (Team-NB) has submitted feedback on the proposed targeted revision of the EU medical...

HRA blog outlines new legal transparency requirements and transitional arrangements ahead of April 2026 implementation

HRA blog outlines new legal transparency requirements and transitional arrangements ahead of April 2026 implementation

The Health Research Authority (HRA) has published a blog outlining new legal research transparency requirements under forthcoming UK clinical trials...

Life Sciences weekly highlights—9 April 2026

Life Sciences weekly highlights—9 April 2026

This week's edition of Life Sciences weekly highlights includes news that the text of the groundbreaking US–UK agreement for tariff-free exports of...

Featured Life Sciences content

Introduction to technology transfer agreements in the Life Sciences industry

Introduction to technology transfer agreements in the Life Sciences industry

Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...

Regulation of cosmetic products in the UK

Regulation of cosmetic products in the UK

Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...

Intellectual property protection for medical devices

Intellectual property protection for medical devices

Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...

Second and subsequent medical use patent claims

Second and subsequent medical use patent claims

Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...

Practice notes

The experimental use and Bolar-type exemptions to patent infringement

The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
Read More >
Produced in partnership with Charlie French of Bristows and Milly Wickson of Bristows
13th Oct
tag iconIn-house
News

The 2024 ABPI Code of Practice—what are the key proposed changes?

The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Read More >
3rd Jun
Precedents

Clinical Research Organisation (CRO) master services agreement

Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
Read More >
30th May
Practice notes

The EU Clinical Trials Regulation

The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Read More >
Produced in partnership with Eveline Van Keymeulen of Latham & Watkins and Jeanne Fabre of Latham & Watkins
13th Oct
Precedents

Medical devices due diligence questionnaire

Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Read More >
30th May
Flowcharts

Lifecycle of a medical device—flowchart

Lifecycle of a medical device—flowchartThis Flowchart illustrates the typical lifecycle of a medical device. The lifecycle identifies eight key stages...
Read More >
2nd Jun
Practice notes

Biotechnology patents

Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Read More >
Produced in partnership with Nicole Jadeja of Pinsent Masons and Christopher Leung of Fieldfisher
13th Oct
Practice notes

Unlicensed medicinal products and off-label use of medicinal products

Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
Read More >
Produced in partnership with Dr Peter Feldschreiber of 4 New Square
13th Oct
News

MHRA releases guidance on pharmacovigilance following Windsor Framework agreement

The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
Read More >
3rd Jun
Practice notes

The regulation of medical devices in the UK

The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
Read More >
30th May
tag iconBrexit
News

Court of Appeal allows appeal in British Standards v RRR Manufacturing

The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
Read More >
3rd Jun
News

CMA announces Phase 1 merger inquiry into Roche Diagnostics

The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
Read More >
3rd Jun
News

DSIT publishes international scientific report on advanced AI safety

The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
Read More >
3rd Jun
Practice notes

The regulation of advanced therapy medicinal products

The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
Read More >
Produced in partnership with Alexander Roussanov of Arnold & Porter and Heba Jalil of Arnold & Porter
13th Oct
Practice notes

Intellectual property protection for digital health

Intellectual property protection for digital healthThis Practice Note discusses the various intellectual property (IP) rights that can be used to...
Read More >
Produced in partnership with Dr. Fiona Kellas of Maucher Jenkins
13th Oct
News

Competition Appeal Tribunal upholds £130m in Allergan fines

...
Read More >
2nd Jun

Popular documents

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an